World Health Organization [Internet]. Hepatitis C. [cited 2023 April 22]. Available from:
https://www.who.int/news-room/fact-sheets/detail/hepatitis-c.
Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al. Hepatocellular
carcinoma. Nat Rev Dis Primers. 2016;2:16018.
Vermehren J, Park JS, Jacobson IM, Zeuzem S. Challenges and perspectives of direct antivirals for the
treatment of hepatitis C virus infection. J Hepatol. 2018;69(5):1178–1187.
Heffernan A, Cooke GS, Nayagam S, Thursz M, Hallett TB. Scaling up prevention and treatment towards
the elimination of hepatitis C: a global mathematical model. Lancet. 2019;393(10178):1319–1329.
Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective
therapies. Nat Med. 2013;19(7):837–849.
Deng L, Shoji I, Ogawa W, Kaneda S, Soga T, Jiang DP, et al. Hepatitis C virus infection promotes hepatic
gluconeogenesis through an NS5A-mediated, FoxO1-dependent pathway. J Virol. 2011;85(17):8556–8568.
Deng L, Adachi T, Kitayama K, Bungyoku Y, Kitazawa S, Ishido S, et al. Hepatitis C virus infection
induces apoptosis through a Bax-triggered, mitochondrion-mediated, caspase 3-dependent pathway. J Virol.
2008;82(21):10375–10385.
Deng L, Liang Y, Ariffianto A, Matsui C, Abe T, Muramatsu M, et al. Hepatitis C Virus-Induced ROS/JNK
Signaling Pathway Activates the E3 Ubiquitin Ligase Itch to Promote the Release of HCV Particles via
Polyubiquitylation of VPS4A. J Virol. 2022;96(6):e0181121.
Curran T, Franza BR Jr. Fos and Jun: the AP-1 connection. Cell. 1988;55(3):395–397.
Zeke A, Misheva M, Remenyi A, Bogoyevitch MA. JNK Signaling: Regulation and Functions Based on
Complex Protein-Protein Partnerships. Mol Biol Rev. 2016;80(3):793–835.
Li B, Tournier C, Davis RJ, Flavell RA. Regulation of IL-4 expression by the transcription factor JunB
during T helper cell differentiation. EMBO J. 1999;18(2):420–432.
Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene. 2001;20(19):2390–2400.
Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer. 2003;3(11):859–868.
Passegue E, Wagner EF. JunB suppresses cell proliferation by transcriptional activation of p16(INK4a)
expression. EMBO J. 2000;19(12):2969–2979.
Bergman MR, Cheng S, Honbo N, Piacentini L, Karliner JS, Lovett DH. A functional activating protein 1
(AP-1) site regulates matrix metalloproteinase 2 (MMP-2) transcription by cardiac cells through
interactions with JunB-Fra1 and JunB-FosB heterodimers. Biochem J. 2003;369(Pt 3):485–496.
Hezode C, Cazeneuve C, Coue O, Roudot-Thoraval F, Lonjon I, Bastie A, et al. Liver iron accumulation in
patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and
relationship with hepatic histological lesions. J Hepatol. 1999;31(6):979–984.
Silva IS, Perez RM, Oliveira PV, Cantagalo MI, Dantas E, Sisti C, et al. Iron overload in patients with
JUNB SUPPRESSES HCV REPLICATION
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
chronic hepatitis C virus infection: clinical and histological study. J Gastroenterol Hepatol.
2005;20(2):243–248.
Tanaka H, Fujita N, Sugimoto R, Urawa N, Horiike S, Kobayashi Y, et al. Hepatic oxidative DNA damage
is associated with increased risk for hepatocellular carcinoma in chronic hepatitis C. Br J Cancer.
2008;98(3):580–586.
Schmidt PJ. Regulation of Iron Metabolism by Hepcidin under Conditions of Inflammation. J Biol Chem.
2015;290(31):18975–18983.
Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular
iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090–2093.
Kanamori Y, Murakami M, Matsui T, Funaba M. JNK facilitates IL-1beta-induced hepcidin transcription
via JunB activation. Cytokine. 2018;111:295–302.
Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for subgenomic and genomic hepatitis C
virus RNA replication. J Virol. 2002;76(24):13001–13014.
Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, et al. Complete replication of
hepatitis C virus in cell culture. Science. 2005;309(5734):623–626.
Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C
virus in tissue culture from a cloned viral genome. Nat Med. 2005;11(7):791–796.
Murakami K, Ishii K, Ishihara Y, Yoshizaki S, Tanaka K, Gotoh Y, et al. Production of infectious hepatitis C
virus particles in three-dimensional cultures of the cell line carrying the genome-length dicistronic viral
RNA of genotype 1b. Virology. 2006;351(2):381–392.
Wozniak AL, Griffin S, Rowlands D, Harris M, Yi M, Lemon SM, et al. Intracellular proton conductance of
the hepatitis C virus p7 protein and its contribution to infectious virus production. PLoS Pathog.
2010;6(9):e1001087.
Meynard D, Babitt JL, Lin HY. The liver: conductor of systemic iron balance. Blood.
2014;123(2):168–176.
Muckenthaler MU, Rivella S, Hentze MW, Galy B. A Red Carpet for Iron Metabolism. Cell.
2017;168(3):344–361.
Foka P, Dimitriadis A, Karamichali E, Kyratzopoulou E, Giannimaras D, Koskinas J, et al. Alterations in
the iron homeostasis network: A driving force for macrophage-mediated hepatitis C virus persistency.
Virulence. 2016;7(6):679–690.
Sugimoto R, Fujita N, Tomosugi N, Hara N, Miyachi H, Tanaka H, et al. Impaired regulation of serum
hepcidin during phlebotomy in patients with chronic hepatitis C. Hepatol Res. 2009;39(6):619–624.
Liu H, Trinh TL, Dong H, Keith R, Nelson D, Liu C. Iron regulator hepcidin exhibits antiviral activity
against hepatitis C virus. PLoS One. 2012;7(10):e46631.
Fillebeen C, Rivas-Estilla AM, Bisaillon M, Ponka P, Muckenthaler M, Hentze MW, et al. Iron inactivates
the RNA polymerase NS5B and suppresses subgenomic replication of hepatitis C Virus. J Biol Chem.
2005;280(10):9049–9057.
Fillebeen C, Pantopoulos K. Iron inhibits replication of infectious hepatitis C virus in permissive Huh7.5.1
cells. J Hepatol. 2010;53(6):995–999.
E95
...
論文の公開元へ
